COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.
Adult
Antirheumatic Agents
/ therapeutic use
Betacoronavirus
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
/ methods
Communicable Disease Control
/ methods
Coronavirus Infections
/ diagnosis
Female
Humans
Hydroxychloroquine
/ therapeutic use
Italy
/ epidemiology
Lupus Erythematosus, Systemic
/ epidemiology
Male
Middle Aged
Pandemics
/ prevention & control
Patient Compliance
/ statistics & numerical data
Pneumonia, Viral
/ epidemiology
Prevalence
Qualitative Research
SARS-CoV-2
Social Isolation
/ psychology
Symptom Assessment
/ methods
COVID-19
Coronavirus
Epidemiology
Hydroxychloroquine
Systemic lupus erythematosus
Web
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
09
05
2020
revised:
12
06
2020
accepted:
22
06
2020
pubmed:
15
9
2020
medline:
6
11
2020
entrez:
14
9
2020
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a chronic disease characterised by autoimmunity and increased susceptibility to infections. COVID-19 is a systemic viral disease currently spreading as a pandemic. Little is known about the impact of COVID-19 in patients with SLE. to acquire information on the impact of COVID-19 in SLE. A 26-item anonymous questionnaire investigating demographics, SLE clinical features, COVID-19 diagnoses and changes in treatments and daily habits was administered to patients with SLE from three referral centres through www.surveymonkey.com over 10 days. Data from the survey were compared to those from published estimates about the general population. Four-hundred-seventeen patients responded to the survey. More than 60% of subjects complained of symptoms that are also associated to COVID-19. Fourteen COVID-19 diagnoses (five confirmed by polymerase chain reaction) were reported, in contrast to a 0.73% prevalence of confirmed cases in Lombardy. One hospitalisation was reported. Fever, anosmia, dry cough, a self-reported history of neuropsychiatric SLE and a recent contact with confirmed COVID-19 cases were more strongly associated with COVID-19, as were symptoms and lower compliance to behavioural preventive measures in patients' contacts. No protective effect was seen in subjects on hydroxychloroquine. COVID-19 morbidity might only moderately be increased in most patients with SLE, although limited information can be inferred on more severe cases. Hydroxychloroquine apparently seems not to confer protection to infection per se, although other beneficial roles cannot be excluded. Containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE.
Sections du résumé
BACKGROUND
Systemic lupus erythematosus (SLE) is a chronic disease characterised by autoimmunity and increased susceptibility to infections. COVID-19 is a systemic viral disease currently spreading as a pandemic. Little is known about the impact of COVID-19 in patients with SLE.
OBJECTIVE
to acquire information on the impact of COVID-19 in SLE.
METHODS
A 26-item anonymous questionnaire investigating demographics, SLE clinical features, COVID-19 diagnoses and changes in treatments and daily habits was administered to patients with SLE from three referral centres through www.surveymonkey.com over 10 days. Data from the survey were compared to those from published estimates about the general population.
RESULTS
Four-hundred-seventeen patients responded to the survey. More than 60% of subjects complained of symptoms that are also associated to COVID-19. Fourteen COVID-19 diagnoses (five confirmed by polymerase chain reaction) were reported, in contrast to a 0.73% prevalence of confirmed cases in Lombardy. One hospitalisation was reported. Fever, anosmia, dry cough, a self-reported history of neuropsychiatric SLE and a recent contact with confirmed COVID-19 cases were more strongly associated with COVID-19, as were symptoms and lower compliance to behavioural preventive measures in patients' contacts. No protective effect was seen in subjects on hydroxychloroquine.
CONCLUSION
COVID-19 morbidity might only moderately be increased in most patients with SLE, although limited information can be inferred on more severe cases. Hydroxychloroquine apparently seems not to confer protection to infection per se, although other beneficial roles cannot be excluded. Containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE.
Identifiants
pubmed: 32927376
pii: S0049-0172(20)30194-3
doi: 10.1016/j.semarthrit.2020.06.012
pmc: PMC7836639
pii:
doi:
Substances chimiques
Antirheumatic Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1157Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest in connection with this paper
Références
Presse Med. 2014 Jun;43(6 Pt 2):e167-80
pubmed: 24855048
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Rheum Dis. 2020 Sep;79(9):1252-1253
pubmed: 32345617
Nat Rev Rheumatol. 2010 Jan;6(1):10-1
pubmed: 20046202
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
Crit Care Resusc. 2020 Apr 15;22(2):95-97
pubmed: 32294809
Ann Rheum Dis. 2020 Jun;79(6):e61
pubmed: 32295787
Rheumatol Adv Pract. 2018;2(1):rky003
pubmed: 31276088
Clin Immunol. 2020 Jun;215:108410
pubmed: 32276140
J Rheumatol. 2017 Jul;44(7):1032-1038
pubmed: 28507183
Lupus. 2006;15(9):577-83
pubmed: 17080912
Acta Biomed. 2020 Apr 10;91(3-S):175-179
pubmed: 32275287
Arthritis Rheumatol. 2017 Oct;69(10):2029-2037
pubmed: 28605137
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
Rheumatology (Oxford). 2008 Jun;47(6):920-3
pubmed: 18411213
N Engl J Med. 2011 Dec 1;365(22):2110-21
pubmed: 22129255
J Clin Med. 2020 May 21;9(5):
pubmed: 32455807
Sci Transl Med. 2011 Mar 9;3(73):73ra20
pubmed: 21389264
JAMA Health Forum. 2020 Apr 1;1(4):e200438
pubmed: 36218613
Rheumatology (Oxford). 2013 May;52(5):905-9
pubmed: 23307831
Front Immunol. 2018 May 17;9:1088
pubmed: 29868033
Nat Med. 2016 Feb;22(2):146-53
pubmed: 26779811
Lupus. 2008 Apr;17(4):281-8
pubmed: 18413408
Trends Immunol. 2017 May;38(5):373-382
pubmed: 28274696
Sci Rep. 2016 Dec 02;6:37817
pubmed: 27910867
Curr Opin Rheumatol. 2016 Jul;28(4):398-404
pubmed: 26986247
J Immunol. 2011 Jul 1;187(1):538-52
pubmed: 21613614
Lancet Rheumatol. 2020 May;2(5):e250-e253
pubmed: 32309814
Lupus. 2013 Oct;22(12):1286-94
pubmed: 24098001
J Rheumatol. 1992 Oct;19(10):1559-65
pubmed: 1464868
Nat Med. 2020 Apr;26(4):618-629
pubmed: 32094927
Arthritis Care Res (Hoboken). 2013 Jul;65(7):1121-7
pubmed: 23818263
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Ann Rheum Dis. 2021 Feb;80(2):e18
pubmed: 32321723
Arthritis Rheum. 1995 Nov;38(11):1660-71
pubmed: 7488288
Ann Rheum Dis. 2020 Jun;79(6):837-839
pubmed: 32332072